UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/559,687	05/11/2006	Jian Ding	035394-0306	2990
54077 7590 12/15/2008 CIPHERGEN c/o FOLEY & LARDNER LLP 3000 K STREET NW SUITE 500 WASHINGTON, DC 20007			EXAMINER	
			GRUN, JAMES LESLIE	
			ART UNIT	PAPER NUMBER
			1641	
			MAIL DATE	DELIVERY MODE
			12/15/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/559,687	DING ET AL.			
Office Action Summary	Examiner	Art Unit			
	JAMES L. GRUN	1641			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1) Responsive to communication(s) filed on 12 Se	eptember 2008.				
• • • • • • • • • • • • • • • • • • • •	action is non-final.				
<i>,</i> —	· 				
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
- 4)⊠ Claim(s) <u>1-4,7-10 and 12-18</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-4,7-10 and 12-18</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	election requirement.				
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
Attachmont/e\					
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date					
3) Information Disclosure Statement(s) (PTO/SB/08) 5) Notice of Informal Patent Application 6) Other:					
Paper No(s)/Mail Date 6)					

Art Unit: 1641

The amendment filed 12 September 2008 is acknowledged and has been entered. Claims 5, 6, 11, and 19-56 have been cancelled. Claims 1-4, 7-10, and 12-18 remain in the case.

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The specification is objected to under 35 U.S.C. § 112, first paragraph, as failing to provide an adequate written description of the invention, and failing to adequately teach how to make and/or use the invention, i.e. failing to provide an enabling disclosure.

The specification is objected to and claims 1-4, 7-10, and 12-18 are rejected under 35 U.S.C. § 112, first paragraph, for the reasons of record that the specification contains subject matter which was not described in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, and which was not described in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention, particularly the invention commensurate in scope with these claims. For the reasons of record, applicant does not describe and does not support the general applicability of the findings of biomarker patterns in serum samples of four patients for one to practice the method for diagnosis of myocardial infarction severity with any predictability of success. For example, as set forth, description or indications are lacking with regard to any differences in the levels of galectin-3 in samples from the different patient populations, or with regard to the selection of a sample other

than serum. Similarly to the reasons as set forth, detection of galectin-3 in a patient sample would not predictably indicate myocardial infarction severity in that patient because the marker is known to be present in elevated levels in older individuals (Prolla et al. (US 7,041,449)) or in patients with inflammation (Rabinovich et al. (Biochimica et Biophys. Acta 1572: 274, 2002)) or in patients with various diseases such as cancer (see e.g.: Woo (US 2002/0076738); or, Hsu et al. (US 2002/0155513)) or cirrhotic liver (Hsu et al. (US 2002/0155513)) or rheumatoid arthritis (Ohshima et al. (Arthritis Rheum. 48: 2788, 2003)).

Applicant's arguments filed 12 September 2008 have been fully considered but they are not deemed to be persuasive. Applicant urges that the instant disclosure adequately describes and enables the invention as claimed. This is not found persuasive for the reasons of record and as set forth above. As set forth, absent further written description and guidance from applicant one would have no assurance of the ability to practice the method for diagnosis of myocardial infarction severity with any predictability of success. Again, a patent is granted for a completed invention, not the general suggestion of an idea and how that idea might be developed into the claimed invention.

The specification is objected to and claims 7-10 are rejected under 35 U.S.C. § 112, first paragraph, for reasons similar to those of record, in the prior rejection of the similar subject matter of claims 37, 38, 41, 42, 50, and 51, that the specification contains subject matter which was not described in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, and which was not described in such a way as to enable one skilled in the art to which it pertains, or

with which it is most nearly connected, to make and/or use the invention. Applicant's claims appear drawn to a single affinity capture reagent that can bind galectin-3 and fibrinogen. Applicant's specification does not provide written description for such a reagent and does not teach how to make such a reagent. Absent further written description and guidance from applicant one would have no assurance of the predictable ability to make and use an affinity reagent as instantly claimed.

Applicant's arguments filed 12 September 2008 have been fully considered but they are not deemed to be persuasive. Notwithstanding applicant's assertions to the contrary, applicant's amendments have not obviated rejections under this statute for the reasons set forth above.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-4, 7-10, and 12-18 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claim 1 and claims dependent thereupon, the relationships of the measuring and correlating steps to qualifying severity are not clear because: it is not clear what is being determined because the severity of the infarction appears to be already known for correlating; and, because "severe" and "mild" are relative terms which render the claims indefinite—the terms are not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. In these claims, "the" severity or amount lack antecedent basis.

Art Unit: 1641

In claim 2 it remains unclear how treatment is "based on" severity.

Applicant's arguments filed 12 September 2008 have been fully considered but they are not deemed to be persuasive.

Notwithstanding applicant's assertions to the contrary, applicant's amendments have not obviated rejections under this statute for the reasons set forth above.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR § 1.136(a).

A SHORTENED STATUTORY PERIOD FOR REPLY TO THIS FINAL ACTION IS SET TO EXPIRE **THREE MONTHS** FROM THE MAILING DATE OF THIS ACTION. IN THE EVENT A FIRST REPLY IS FILED WITHIN **TWO MONTHS** OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE **THREE-MONTH** SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR REPLY EXPIRE LATER THAN **SIX MONTHS** FROM THE MAILING DATE OF THIS FINAL ACTION.

Application/Control Number: 10/559,687

Art Unit: 1641

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James L. Grun, Ph.D., whose telephone number is (571) 272-0821. The examiner can normally be reached on weekdays from 11 a.m. to 7 p.m.

Page 6

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark Shibuya, SPE, can be contacted at (571) 272-0806.

The phone number for official facsimile transmitted communications to TC 1600, Group 1640, is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application, or requests to supply missing elements from Office communications, should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/J. L. G./ James L. Grun Examiner, Art Unit 1641 December 15, 2008

/Ann Y. Lam/ Primary Examiner, Art Unit 1641 December 11, 2008